Correlation Between Oncopeptides and Cantargia

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Oncopeptides and Cantargia at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Oncopeptides and Cantargia into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Oncopeptides AB and Cantargia AB, you can compare the effects of market volatilities on Oncopeptides and Cantargia and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Oncopeptides with a short position of Cantargia. Check out your portfolio center. Please also check ongoing floating volatility patterns of Oncopeptides and Cantargia.

Diversification Opportunities for Oncopeptides and Cantargia

-0.03
  Correlation Coefficient

Good diversification

The 3 months correlation between Oncopeptides and Cantargia is -0.03. Overlapping area represents the amount of risk that can be diversified away by holding Oncopeptides AB and Cantargia AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cantargia AB and Oncopeptides is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Oncopeptides AB are associated (or correlated) with Cantargia. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cantargia AB has no effect on the direction of Oncopeptides i.e., Oncopeptides and Cantargia go up and down completely randomly.

Pair Corralation between Oncopeptides and Cantargia

Assuming the 90 days trading horizon Oncopeptides AB is expected to generate 1.45 times more return on investment than Cantargia. However, Oncopeptides is 1.45 times more volatile than Cantargia AB. It trades about 0.07 of its potential returns per unit of risk. Cantargia AB is currently generating about -0.02 per unit of risk. If you would invest  165.00  in Oncopeptides AB on November 29, 2024 and sell it today you would earn a total of  22.00  from holding Oncopeptides AB or generate 13.33% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Oncopeptides AB  vs.  Cantargia AB

 Performance 
       Timeline  
Oncopeptides AB 

Risk-Adjusted Performance

Insignificant

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Oncopeptides AB are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Oncopeptides unveiled solid returns over the last few months and may actually be approaching a breakup point.
Cantargia AB 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Cantargia AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Cantargia is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors.

Oncopeptides and Cantargia Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Oncopeptides and Cantargia

The main advantage of trading using opposite Oncopeptides and Cantargia positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Oncopeptides position performs unexpectedly, Cantargia can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cantargia will offset losses from the drop in Cantargia's long position.
The idea behind Oncopeptides AB and Cantargia AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Other Complementary Tools

Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device